Stockscreener 앱 받기
31.95
3.52%
1.085
시장 영업 전:
31.95
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? - The Motley Fool
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? - The Motley Fool
URGN Stock Price, Quote & Chart - ChartMill
UroGen settles with Teva over Jelmyto patent dispute - MSN
UroGen Pharma CMO Mark Schoenberg sells $142,560 in shares By Investing.com - Investing.com Australia
UroGen Pharma Ltd stock (IL0011408896): Focus on urology pipeline after recent clinical updates - AD HOC NEWS
UroGen Pharma CMO Mark Schoenberg sells $142,560 in shares - Investing.com UK
UroGen Pharma (URGN) Gains Ground: Analyzing the Uptrend Above $27Initial Balance - newsline.com
Insider Sale: Chief Medical Officer of $URGN Sells 5,222 Shares - Quiver Quantitative
UroGen Pharma (URGN) CMO nets shares as RSUs vest and 5,222 sold for tax - Stock Titan
Mark Schoeberg sells 10,000 shares of UroGen (URGN) reported in Form 144 - Stock Titan
How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment Story - simplywall.st
UroGen Pharma (URGN) Gains Ground: Positive Momentum Breaks Key ThresholdVolume Breakout Ideas - newsline.com
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth - ChartMill
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative? - Yahoo Finance
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Assessing UroGen Pharma (URGN) Valuation After Jelmyto Patent Settlement With Teva - simplywall.st
(URGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma Ltd stock (IL0011408896): Nasdaq inducement grants and valuation metrics in focus - AD HOC NEWS
UroGen Pharma, Teva End Patent Dispute Over Urinary Cancer Drug - Bloomberg Law News
URGN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
UroGen Pharma stock reaffirmed at Buy by H.C. Wainwright on Teva settlement - Investing.com South Africa
Oppenheimer reiterates Outperform on UroGen Pharma stock after Teva settlement - Investing.com Australia
UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA) - GuruFocus
[8-K] UroGen Pharma Ltd. Reports Material Event - Stock Titan
UroGen Announces Agreement Resolving Patent Litigation - GlobeNewswire
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs - Kavout
Hear UroGen’s Goldman Sachs healthcare chat online with 90-day replay - Stock Titan
UroGen Pharma Ltd stock (IL0011408896): recent gains put valuation in focus - AD HOC NEWS
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge - AOL.com
[ARS] UroGen Pharma Ltd. SEC Filing - Stock Titan
UroGen Pharma (URGN) director converts 2,000 RSUs into ordinary shares, holds 6,000 - stocktitan.net
Liquidity Mapping Around (URGN) Price Events - Stock Traders Daily
URGN: ZUSDURI adoption accelerates with robust Q1 growth and pipeline advances set for 2024-2027 - TradingView
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
How UGN-103’s Phase 3 Data and NDA Timeline Could Reshape UroGen Pharma (URGN) Investors’ Outlook - simplywall.st
1.27%
1.43%
자본화:
|
볼륨(24시간):